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Abstract
Background: Ayurveda is a system of traditional medicine that originated in ancient India, and it is still in practice.
Medicinal plants are the backbone of Ayurveda, which heavily relies on the plant-derived therapeutics. While
Ayurveda is becoming more popular in several countries throughout the World, lack of authenticated medicinal
plant raw drugs is a growing concern. Our aim was to DNA barcode the medicinal plants that are listed in the
Ayurvedic Pharmacopoeia of India (API) to create a reference DNA barcode library, and to use the same to
authenticate the raw drugs that are sold in markets.
Methods: We have DNA barcoded 347 medicinal plants using rbcL marker, and curated rbcL DNA barcodes for 27
medicinal plants from public databases. These sequences were used to create Ayurvedic Pharmacopoeia of India -
Reference DNA Barcode Library (API-RDBL). This library was used to authenticate 100 medicinal plant raw drugs, which
were in the form of powders (82) and seeds (18).
Results: Ayurvedic Pharmacopoeia of India - Reference DNA Barcode Library (API-RDBL) was created with high quality
and authentic rbcL barcodes for 374 out of the 395 medicinal plants that are included in the API. The rbcL DNA barcode
differentiated 319 species (85 %) with the pairwise divergence ranging between 0.2 and 29.9 %. PCR amplification and
DNA sequencing success rate of rbcL marker was 100 % even for the poorly preserved medicinal plant raw drugs that
were collected from local markets. DNA barcoding revealed that only 79 % raw drugs were authentic, and the remaining
21 % samples were adulterated. Further, adulteration was found to be much higher with powders (ca. 25 %) when
compared to seeds (ca. 5 %).
Conclusions: The present study demonstrated the utility of DNA barcoding in authenticating medicinal plant raw drugs,
and found that approximately one fifth of the market samples were adulterated. Powdered raw drugs, which are very
difficult to be identified by taxonomists as well as common people, seem to be the easy target for adulteration.
Developing a quality control protocol for medicinal plant raw drugs by incorporating DNA barcoding as a component is
essential to ensure safety to the consumers.
Background
Ayurveda is one of the most ancient systems of trad-
itional medicine, which originated in India about
5000 years ago [1]. As science of life (‘ayur’ means ‘life’
and ‘veda’ means ‘knowledge’ in Sanskrit), Ayurveda fo-
cuses on the holistic approach towards a healthy life, not
merely on curing of diseases. Ayurveda is based on the
principle that both the universe and the human body are
made up of five elements. A balanced state of these
elements in the body gives good health, and an imbal-
ance brings illness or disease [2]. It is a detailed system
of traditional medicine with eight distinct branches and
16 specialties including internal medicine, surgery (in-
cludes plastic surgery), pediatrics, obstetrics, gynecology,
psychiatry, toxicology, and geriatrics [3]. Ayurveda is not
a simple herbal medicine; it provides a detailed account
of drug preparation using herbs, detoxification and
proper administration with the required dosage. It is the
oldest medical system to offer patient-centric personal-
ized medicine. Therefore, Ayurveda bears all the qual-
ities of a distinct medical system in its own strength.
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However, extensive modern experimental research and
regulatory system are required to make it a standardized,
effective and safe system of medicine.
Owing to the excellent education system that prevailed
in the ancient India, the bibliographic account of Ayur-
veda is well documented. Atharva Veda (1500 to 1000
BC) is considered the first written document of Ayur-
veda containing the description of certain diseases, and
methods of curing them [4]. The two other important
ancient treatises on Ayurveda are Charaka Samhita
(1000 BC), which deals with internal medicine explain-
ing the logic and philosophy of Ayurvedic medicine [5,
6], and Sushruta Samhita (1000 BC), which deals with
surgery, and the diseases of special organs such as the
eye, ear, throat, nose, head and dentistry [7, 8]. These
treatises were used for the institutionalized teaching of
Ayurveda in the Department of Ayurveda, which was
established as early as 7th century in the ancient Taksha-
shila University in India (now in Pakistan) [9]. It is
around this time, Ashtanga Hridaya was written with the
detailed explanation of the principles and practices of
Ayurvedic medicine. Subsequently, many texts, compen-
dia, and updates were written to further expand the
knowledge. However, the principles and philosophy of
Ayurveda remained the same. At present, there are 57
authoritative textbooks for practicing Ayurveda in India
and elsewhere [10].
Ayurveda is being continuously practiced in India
from ancient times, and at present, it is one of the main-
stream official systems of medicine with sufficient infra-
structure for healthcare service and education.
Education in Ayurvedic medicine is offered at the under-
graduate (five and an half year program), postgraduate
(MD/MS in more than 20 specialties), and Ph.D. levels
in India. A huge network of 429,246 registered practi-
tioners, 2420 Ayurveda hospitals and 15,017 dispensaries
offer healthcare to the people [2]. It is also becoming
popular in other countries including Latin American
countries, Europe and the USA [11]. High cost and in-
creasing awareness about the side effects of allopathy
drugs, especially in case of chronic diseases, are the
main driving forces that favor the adoption of nature-
based Ayurvedic medicine.
Until a century ago, all medicines were non-synthetic,
and mostly came from plants. Therefore, it is no surprise
that plants are the major source of therapeutic ingredi-
ents in Ayurveda also. Atharva Veda (1500–1000 BC)
mentions 293 medicinal plants [12]. Charaka Samhita
(1000 BC) and Sushruta Samhita (1000 BC) contain the
names of 341 and 395 medicinal plants, respectively [13,
14]. Ashtanga Hridaya described the largest number of
902 medicinal plants [15]. The medicinal plants in theses
treatises were given simple Sanskrit names much before
the modern Linnaean taxonomy with binomial names
was proposed in the 18th century. Presently, the Ayur-
vedic Pharmacopoeia of India (API) is the legal docu-
ment of standards for the quality of Ayurvedic drugs
and substances included therein [16–21]. The six vol-
umes of API list 395 medicinal plants, which can be offi-
cially used for the preparation of single drugs (each drug
is derived from one plant or plant part). Use of the cor-
rect plant species is the basic requirement to get the de-
sired benefits of Ayurveda. Dwindling natural supplies at
the time of increasing domestic and global demand for
the medicinal plants increases the probability of adulter-
ation, which can greatly affect the efficacy and safety of
Ayurvedic medicine. Morphological species identifica-
tion for monitoring adulteration in plant materials is a
great challenge, especially when the plants are purchased
as raw drugs (dried or powdered whole plant or plant
parts), which often lack the key morphological diagnos-
tic characters that are required for species identification.
The present study is the first attempt to DNA barcode
the medicinal plants that are listed in API so as to de-
velop a molecular tool to identify them in fresh as well
as raw drug form. For this purpose, first we have com-
piled the list of plants in API with currently accepted
scientific names. Then, we have collected fresh plant
specimens and DNA barcoded them to generate Ayur-
vedic Pharmacopoeia of India - Reference DNA Barcode
Library (API-RDBL). Subsequently, this library was used
for species identification by DNA barcoding of the raw
drugs that were collected from markets.
Methods
Collection of plant samples
The monographs in the API contain the Sanskrit and
botanical names of the plants. Since these monographs
were written between the year 1990 and 2008 (Ayur-
vedic Pharmacopoeia of India Part – I, Volumes I to VI),
we have revised the name of the plants by incorporating
the currently accepted botanical names as given in Tro-
picos and The Plants List database. We have prepared
the API plant list that contains the Sanskrit names, the
botanical names used in the API and the currently ac-
cepted botanical names for the 395 plants (see Add-
itional file 1: Table S1). Throughout this study only the
currently accepted botanical names as given in API plant
list were used. Four medicinal plants in the API plant list
are not available in India, and hence imported as raw
drugs from other countries. Some medicinal plants in
the API plant list were difficult to collect due to their
seasonal occurrence or distribution in the high altitude
ranges of the Himalayas. Most of the fresh specimens of
the medicinal plants were collected from open forests,
cultivated fields and botanical gardens of research insti-
tutions. Some specimens were derived from the seed-
lings that were raised from seeds in the greenhouse.
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Altogether, we have collected fresh specimens for 347
medicinal plants in the API plant list. Name of the plant,
Sample ID, Field ID, and the place of collection are given
in (see Additional file 2: Table S2). Voucher specimens
were prepared and identified using local floras, mounted
on standard herbarium sheets, and deposited in the
SRM University Herbarium. Fresh leaves were used for
DNA isolation, and air-dried samples were retained for
future reference.
Curated data from public databases
The GenBank and BOLD databases were searched for
the presence of rbcL sequences from the medicinal
plants for which we could not collect specimens for
DNA isolation. The curated rbcL barcodes from these
databases were included in the present study.
Collection of raw drugs
Samples of the medicinal plant raw drugs in the form of
powders and seeds were collected from the herbal mar-
kets in Chennai, Tamil Nadu, India.
DNA extraction, PCR amplification and sequencing
Genomic DNA was extracted from either 100 mg of fresh
leaf tissue or 25 mg of raw drugs using the cetyl trimethyl
ammonium bromide (CTAB) method [22] as described be-
fore [23]. The DNA was checked on 0.8 % Agarose gel and
quantified for PCR amplification. Polymerase chain reaction
(PCR) was performed using rbcLaF (ATGTCACCACAAA-
CAGAGACTAAAGC), rbcLajf634R (GAAACGGTCTCTC
CAACGCAT) primers [24, 25]. The amplicons were
checked on 1 % agarose gel, and purified using EZ-10 Spin
Column PCR Purification Kit (Bio Basic Inc. Ontario,
Canada). Samples were sequenced using 3130xl Genetic
analyzer (Applied Biosystems, CA, USA). The sequences
were manually edited using Sequence Scanner Software
v1.0 (Applied Biosystems, CA, USA), and full-length se-
quences were assembled using local alignment algorithm of
CodonCode Aligner, version 4.2.4 (CodonCode Corpor-
ation, MA, USA).
Sequence analyses
BLAST search was performed against GenBank (http://
blast.ncbi.nlm.nih.gov/Blast.cgi) and BOLD (http://
www.boldsystems.org/index.php/databases) databases.
TaxonDNA v. 1.6.2 (http://taxondna.sf.net/) was used to
calculate pairwise divergence [26]. Phylogenetic tree
based on Neighbour-Joining (NJ) method was con-
structed using MEGA version 5.1 [27]. Best match
method was used for the authentication of the raw drug
market samples [26]. Unmatched samples were analyzed
by BLAST search against the NCBI nucleotide database
and BOLD database.
Results and discussion
It is estimated that about 1587 plants are used for the
preparation of various kinds of Ayurvedic medicines
[28]. Ayurvedic Pharmacopoeia of India (API) officially
recommends 395 medicinal plants for the preparation of
519 Ayurvedic single drugs. The present study included
347 of them, which belong to 308 genera, 112 families
and 45 orders. DNA isolation, PCR amplification and
DNA sequencing of the rbcL marker were successful
with all these plants. The same level of success was ob-
served with the raw drugs, which were stored at room
temperature without any special care to preserve the
DNA. Therefore, rbcL would be a robust marker for cre-
ating reference DNA barcode library for the API plants,
and authenticating poorly preserved market samples.
Size of the rbcL barcodes generated in the present study
was 607 bp with the Q value ≥ 40. Being a highly con-
served and maternally inherited chloroplast marker, rbcL
query sequence is expected to show the highest identity
with the sequence from the same species or closely re-
lated species. Therefore, nucleotide BLAST analysis of
the rbcL sequences can be used as a quality control
measure to flag potential morphological misidentifica-
tions or sample mix up. In nucleotide BLAST analysis,
the rbcL sequences from all the 347 medicinal plants
showed the highest identity with sequences from the
same species (148) or congeneric species (145) or species
from a closely related genus of the same family (54).
These results provided initial DNA based validation for
the taxonomic identity of the medicinal plants that were
collected for the current study. However, this validation
will not be reliable if the taxonomic identity of the se-
quence in the database was incorrect. This problem can
be addressed by constructing phylogenetic tree wherein
the wrongly identified samples are highly likely to be
placed in unexpected clades. As shown in Fig. 1, the
phylogenetic tree showed placing of all the species in ap-
propriate clades as would be expected based on phylo-
genetic relationships among the flowering plants as per
APG III classification. Therefore, taxonomic fidelity of
the rbcL sequences that was generated from the current
study can be considered as high. These sequences were
submitted to the BOLD Systems under the accession
numbers [SRM301A to SRM600A and SRM618A to
SRM671A].
In addition, we have supplemented our data by adding
rbcL sequences for 27 plants, which were curated from
GenBank and BOLD databases. All the curated sequence
data satisfied the criteria of i) the sequence is associated
with publications in refereed journals or unpublished
data from scientists with good publication record in tax-
onomy or DNA barcoding, ii) the sequence shows high-
est identity with sequences from congeneric species, iii)
the sequence is placed in the clade that is appropriate to
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its taxonomic affiliation (Fig. 1), and iv) at least one se-
quence of 500 bp length is available. Details of the 27
medicinal plants in the API plant list for which the rbcL
sequences were curated from GenBank and BOLD data-
bases are given in Additional file 3: Table S3 [29–43].
Size of the curated rbcL sequences ranged between 502
and 607 bp. Since the Consortium for the Barcode of
Life (CBOL) recommends 500 bp as acceptable DNA
barcode size, all the sequences included in our study are
suitable to be used as DNA barcode marker. Together,
rbcL sequences from 374 medicinal plants were used to
generate Ayurvedic Pharmacopoeia of India - Reference
DNA Barcode Library (API-RDBL).
Pairwise divergence was calculated to determine the
ability of the rbcL marker to differentiate the 374 species
that are currently represented in the API-RDBL. It was
Fig. 1 Phylogenetic tree constructed using Neighbour-Joining (NJ) method for 374 rbcL sequences for the Ayurvedic Pharmacopoeia of India - Reference
DNA Barcode Library (API-RDBL)
Vassou et al. BMC Complementary and Alternative Medicine 2016, 16(Suppl 1):186 Page 12 of 15
found that 319 species (85 %) could be successfully dif-
ferentiated with the pairwise divergence ranging between
0.2 and 29.9 %. There were 55 undifferentiated species,
which included 38 congeneric species from 17 genera,
each with 2 to 6 species. Differentiation of these species
would require the use of other coding (matK) or non-
coding markers (trnH-psbA, ITS2, and others). Alterna-
tively, a tiered approach of combining one coding
marker with another non-coding marker can be more ef-
fective as it helps to overcome the problem in alignment
that is encountered with the sequences from non-coding
markers. In this approach, a structurally conserved
marker acts as scaffold (first tier marker) on which the
data from a variable noncoding marker is placed [44,
45]. Due to its high universality, and unparalleled PCR
amplification and DNA sequencing success rates, rbcL
could be considered as an ideal first tier marker. The
rbcL marker is particularly useful in DNA barcoding of
the medicinal plants used in Ayurveda because the
major application for it would be the authentication of
raw drugs, which necessitates amplification of the bar-
code sequences from taxonomically diverse and poorly
preserved market samples. Recently, Parvathy et al.
(2015) reported that rbcL but not matK could be ampli-
fied from the market samples of turmeric powders [46].
Excepting a few practitioners who make their own col-
lections, the plant materials used in Ayurveda are nor-
mally procured as raw drugs from the markets.
Therefore, these raw drugs must be authentic to derive
the expected benefits of the Ayurvedic medicines that
are made out of them. However, the raw drugs trade is
largely unregulated, and as a result, spurious raw drugs
are often found in the markets. Adulterations in the
range of 18 to 59 % were reported in the herbal prod-
ucts, commercial medicinal plants, and natural health
products [47–49]. DNA barcoding is undoubtedly having
a high impact on quality control of herbal products and
raw drugs [49, 50]. Therefore, we have explored the pos-
sibility of using the API-RDBL to authenticate the raw
drugs of the medicinal plants that are in the API plant
list. We have collected 100 raw drugs: 82 in the form of
powders and 18 in the form of seeds. Vernacular name
of the raw drug (Tamil), name of the corresponding me-
dicinal plant (Sanskrit name as given in the API), and
currently accepted botanical name are given in (see Add-
itional file 4: Table S4). The rbcL reference sequences
(derived from the corresponding plant specimens) for all
these 100 raw drugs were present in the API-RDBL. Ex-
traction of genomic DNA and DNA sequencing of the
rbcL marker were successful with all the raw drugs. By
comparing these sequences with that in the API-RDBL,
only 79 raw drugs were found to be authentic as their
rbcL sequences showed 100 % identity with the reference
sequence of the expected species. The remaining 21 raw
drugs (21 %) were found to be not authentic as their
rbcL sequences showed only 85 to 98 % identity with the
reference sequence of the expected species. Obviously,
these raw drugs must be eliminated from the markets
because Ayurvedic medicines that are made out of such
spurious raw drugs are not likely to give the desired
therapeutic effects. It may also give adverse or toxic ef-
fect depending on the nature of the plant materials that
are present in the unauthentic raw drugs. Interestingly,
unauthentic raw drugs were significantly more frequent
in powders than in seeds (ca. 25 % versus ca. 5 %). The
possible reason is that the plant parts after grinding to
powders are very difficult for the morphological identifi-
cation by taxonomists or common people, which makes
them vulnerable for adulteration. On the other hand,
seeds have the same morphology as plant part and as
raw drug, which makes it easier for identification and
less vulnerable to adulteration.
It is beyond the scope of this study to establish the
species identity of the plant materials that are present in
the unauthentic raw drugs. However, BLAST analysis of
the rbcL sequences from theses samples against the Gen-
Bank and BOLD databases indicated that the raw drug
samples named as Abies spectabilis and Glycyrrhiza gla-
bra might have been actually derived from Taxus fuana
and Azadirachta indica, respectively. Abies spectabilis is
used in Ayurveda for the treatment of asthma, cough,
abdominal lump, digestive impairment, pthisis, hic-
cough, emesis, worm infestation, diseases of the mouth
and tastelessness [19], but we did not find any Ayurvedic
medicinal use for Taxus fuana. While Glycyrrhiza glabra
is used in Ayurveda for the treatment of cough, hoarse-
ness of voice, pthisis, ulcer and gout [16], Azadirachta
indica is used for treating emesis, skin diseases, bleeding
and urinary disorders, nausea, non-healing ulcer, thirst,
fever, burning sensation, cough, asthma, inflammation,
worm infestation, tastelessness, liver disease, heart burn,
and vomiting [20]. These results clearly show the enor-
mity of the problem that might arise due to the use of
unauthentic raw drugs in Ayurveda.
Conclusion
The present study established for the first time a refer-
ence DNA barcode library for the medicinal plants in
the API plant list. It clearly showed that unauthentic me-
dicinal plant raw drugs are sold in the herbal markets,
and DNA barcoding will be highly useful to identify the
same. Other markers are to be explored to identify the
species that were not differentiated by the rbcL marker.
DNA barcoding of the species that are taxonomically
closely related to the authentic species, potential adulter-
ant species, co-occurring species will strengthen this
technology further.
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